Clinical trials: Mild or Moderate Asthma
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Mild or Moderate Asthma
Gemini Symbicort pMDI
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
- Trial name
- NCT00646516
- Testing
- budesonide/formoterol (Symbicort)
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Asthma
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
- Trial name
- NCT00830102
- Testing
- fluticasone propionate, formoterol fumarate
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 64 people
- Sponsor
- SkyePharma AG
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice…
- Trial name
- NCT00449501
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 46 sites in United States
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Approximately 480 (120 per group) would need to complete the 12 weeks of treatments.
- Trial name
- NCT03835871
- Testing
- 400 µg per day Beclomethasone, 200 µg per day Beclomethasone, 100 µg per day Beclomethasone
- Sponsor
- Adamis Pharmaceuticals Corporation
Migraine
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with…
- Trial name
- NCT02905227
- Testing
- CVT-427 (zolmitriptan inhalation powder)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Asthma
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma
The purpose of this study is to study the safety and tolerability in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.
- Trial name
- NCT01137565
- Testing
- AMG 853
- Volunteers
- 23 people
- Sponsor
- Amgen
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose…
- Trial name
- A006-B3 (NCT02210806)
- Testing
- A006 DPI, Proventil® MDI
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174720
- Testing
- Ciclesonide (XRP1526)
- Where
- 11 sites in United States, Brazil and 9 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Asthma
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.
- Trial name
- NCT01370317
- Testing
- MK-1029
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinitis, Rhinoconjunctivitis
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
This is an observational prospective study to assess the tolerability and safety of treatment of SCIT Allergovac Poliplus polymerized in depot presentation.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- APOLO (NCT02844842)
- Testing
- Allergovac Poliplus
- Where
- 15 sites in Spain
- Volunteers
- 152 people
- Sponsor
- Roxall Medicina España S.A
Mild to Moderate Asthma
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.
- Trial name
- NCT02266927
- Testing
- Flovent HFA, OPTINOSE™ FLUTICASONE
- Where
- Ireland
- Volunteers
- 28 people
- Sponsor
- Optinose US Inc.
House Dust Mite Allergy, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT05400811
- Testing
- MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
- Where
- 16 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Inmunotek S.L.
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
- Trial name
- NCT07116889
- Testing
- GB-0895 (SC)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Generate Biomedicines
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
- Trial name
- NCT00449527
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 44 sites in United States
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Asthma
Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
The main objective of this study is to evaluate the efficacy, dose-ranging and initial safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 25 to 180 mcg per dosing in comparison to a DPI Placebo…
- Trial name
- NCT01581177
- Testing
- Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Albuterol MDI 90 mcg/inh
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.